AbbVie Inc (NYSE:ABBV) VP Robert A. Michael sold 992 shares of the stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $120.31, for a total value of $119,347.52. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
Shares of AbbVie Inc (ABBV) opened at $117.98 on Wednesday. AbbVie Inc has a twelve month low of $61.30 and a twelve month high of $125.86. The company has a current ratio of 1.45, a quick ratio of 1.32 and a debt-to-equity ratio of 5.08. The company has a market capitalization of $188,333.59, a price-to-earnings ratio of 35.86, a PEG ratio of 1.13 and a beta of 1.61.
AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Friday, January 26th. The company reported $1.48 EPS for the quarter, beating the consensus estimate of $1.44 by $0.04. AbbVie had a return on equity of 152.78% and a net margin of 18.82%. The firm had revenue of $7.74 billion during the quarter, compared to analyst estimates of $7.53 billion. During the same quarter in the prior year, the business posted $1.20 EPS. The business’s revenue for the quarter was up 13.9% compared to the same quarter last year. sell-side analysts expect that AbbVie Inc will post 7.46 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, May 15th. Stockholders of record on Friday, April 13th will be issued a dividend of $0.96 per share. This represents a $3.84 annualized dividend and a dividend yield of 3.25%. The ex-dividend date of this dividend is Thursday, April 12th. This is a positive change from AbbVie’s previous quarterly dividend of $0.71. AbbVie’s dividend payout ratio is currently 86.32%.
Several research analysts recently issued reports on the company. BMO Capital Markets reissued a “sell” rating and issued a $95.00 price objective on shares of AbbVie in a research note on Thursday, February 15th. Piper Jaffray Companies upped their target price on AbbVie from $130.00 to $138.00 and gave the stock an “overweight” rating in a report on Thursday, February 15th. Argus upped their target price on AbbVie from $120.00 to $145.00 and gave the stock a “buy” rating in a report on Friday, February 2nd. ValuEngine upgraded AbbVie from a “hold” rating to a “buy” rating in a report on Friday, February 2nd. Finally, Morgan Stanley upped their target price on AbbVie from $99.00 to $131.00 and gave the stock an “equal weight” rating in a report on Tuesday, January 30th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $118.44.
Several institutional investors and hedge funds have recently modified their holdings of the company. Hudock Capital Group LLC raised its stake in AbbVie by 109.5% in the 2nd quarter. Hudock Capital Group LLC now owns 1,542 shares of the company’s stock worth $111,000 after acquiring an additional 806 shares during the last quarter. Ffcm LLC raised its stake in AbbVie by 167.2% in the 2nd quarter. Ffcm LLC now owns 1,539 shares of the company’s stock worth $111,000 after acquiring an additional 963 shares during the last quarter. Bristlecone Advisors LLC purchased a new position in AbbVie in the 3rd quarter worth $113,000. BDO Wealth Advisors LLC purchased a new position in AbbVie in the 2nd quarter worth $115,000. Finally, Truewealth LLC purchased a new position in AbbVie in the 4th quarter worth $126,000. Hedge funds and other institutional investors own 69.49% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece was first posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright legislation. The original version of this piece can be accessed at https://www.chaffeybreeze.com/2018/02/21/abbvie-inc-abbv-vp-sells-119347-52-in-stock.html.
AbbVie Company Profile
AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.